-Heinz-Josef Lenz Researcher Activity Profile

Research Author Detailed Information 

Heinz-Josef Lenz Publication Rate By Year

Heinz-Josef Lenz has published 1 paper(s) in 1989, 1 paper(s) in 1991, 1 paper(s) in 2004, 18 paper(s) in 2007, 9 paper(s) in 2008, for a total of 30 research publications in total.

Heinz-Josef Hj Lenz Author Information

LAST NAME: lenz

FIRST NAME: Heinz-Josef

INITIALS: hj

AFFILIATION:

Papers

Heinz-Josef Lenz's Publication Record

1. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Year Published: 2007
Department of Preventive Medicine, Humboldt-University, Berlin, Germany.
2. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. Year Published: 2007
Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. saltzl@MSKCC.ORG
3. Management and preparedness for infusion and hypersensitivity reactions. Year Published: 2007
University of Southern California, Los Angeles, USA. lenz@usc.edu
4. Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. Year Published: 2007
Coalition of Cancer Cooperative Groups, Philadelphia, PA, USA. peter.odwyer@uphs.upenn.edu
5. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Year Published: 2007
City of Hope Comprehensive Cancer Center, Duarte, California, USA.
6. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. Year Published: 2007
Division of Medical Oncology, Department of Pathology, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA.
7. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. Year Published: 2007
Division of Medical Oncology, Department of Preventive Medicine, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA.
8. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Year Published: 2007
Department of Pathology, Keck School of Medicine, Oncology, University of Southern California/Norris Comprehensive Cancer Center, 14412 Eastlake Avenue, Los Angeles, CA 90033, USA.
9. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. Year Published: 2007
Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. saltzl@MSKCC.ORG
10. Molecular prognostic markers in locally advanced colon cancer. Year Published: 2007
Division of Medical Oncology, Sharon A. Carpenter Laboratory, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA.
11. Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. Year Published: 2004
University of Southern California, Kenneth Norris Comprehensive Cancer Center, Division of Medical Oncology, 1441 Eastlake Avenue, Suite 3457, Los Angeles, CA 90033, USA. iqbal_s@ccnt.hsc.usc.edu
12. Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia. Year Published: 2007
Corresponding author: Agustin A. Garcia, University of Southern California, Norris Comprehensive Cancer Center, 1441 Eastlake Ave, MS 34, Los Angeles, CA 90033; e-mail: aagarcia@usc.edu.
13. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. Year Published: 2008
Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
14. Molecular prognostic markers in locally advanced colon cancer. Year Published: 2007
Division of Medical Oncology, Sharon A. Carpenter Laboratory, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA.
15. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. Year Published: 2008
Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
16. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. Year Published: 2007
University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA. aagarcia@usc.edu
17. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Year Published: 2008
aDivision of Medical Oncology Departments of bPreventive Medicine cPathology, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California, USA.
18. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. Year Published: 2008
Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
19. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Year Published: 2007
Department of Pathology, Keck School of Medicine, Oncology, University of Southern California/Norris Comprehensive Cancer Center, 14412 Eastlake Avenue, Los Angeles, CA 90033, USA.
20. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. Year Published: 2007
University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA. aagarcia@usc.edu
21. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. Year Published: 2008
Case Comprehensive Cancer Center, Ireland Cancer Center at University Hospitals of Case Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA.
22. [The status of intraperitoneal chemotherapy] Year Published: 1989
23. [Central nervous system regulation of gastric acid and duodenal bicarbonate secretion] Year Published: 1991
24. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Year Published: 2007
University of Southern California/Norris Comprehensive Cancer Center, Division of Medical Oncology, The Sharon Carpenter Laboratory, Keck School of Medicine, 1441 Eastlake Avenue, Suite 3456, Los Angeles, CA 90033, USA.
25. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. Year Published: 2007
Department of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA. saltzl@MSKCC.ORG
26. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. Year Published: 2007
Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA. saltzl@mskcc.org
27. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Year Published: 2008
Division of Medical Oncology, Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California 90033, USA.
28. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. Year Published: 2008
Case Comprehensive Cancer Center, Ireland Cancer Center at University Hospitals of Case Medical Center and Case Western Reserve University School of Medicine, Cleveland, OH, USA.
29. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Year Published: 2008
Division of Medical Oncology, Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California 90033, USA.
30. Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis. Year Published: 2008
Department of Surgical Oncology, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan. h-kobayashi.srg2@tmd.ac.jp